Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 8th June 2018
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Study highlights scale of field trials for bovine TB vaccine
As many as 100,000 cattle would be needed to show the effect of a vaccine on bTB transmission.
Researchers propose smaller, natural transmission experiments

New research has highlighted the cost and scale of field trials for bovine TB (bTB).

Writing in the journal eLife, researchers show that as many as 100,000 cattle would be needed to show the effect of a vaccine on bTB transmission. They suggest that this scale and cost could be dramatically reduced by using smaller, less expensive experiments.

“We already know that the BCG vaccine has the potential to protect cattle from bovine TB infection,” explains first author Dr Andrew Conlan from the University of Cambridge’s department of veterinary medicine. “Our results highlight the enormous scale of trials that would be necessary to evaluate BCG alongside continuing testing in the field.

“Such trials would be hugely expensive, and it isn’t even clear whether enough farms could be recruited.”

The researchers propose a natural transmission experiment that involves housing a mixture of vaccinated and unvaccinated cattle with a number of infected cattle. They argue that such an experiment could show the efficacy of vaccination, using as little as 200 cattle.

In the UK, the bTB strategy is to ‘test and slaughter’ infected animals. Whilst the BCG vaccine does exist, it can cause some cattle to test positive falsely.

The BCG vaccine is currently banned in Europe. However, the European Union has stated that it would consider relaxing its laws if the UK government could show that a vaccine is effective on farms.

“If we could consider replacing test-and-slaughter with vaccination, then the economics becomes much more attractive particularly in lower income countries,” explained professor James Wood, head of Cambridge’s department of veterinary medicine.

“Then we would no longer need to carry out expensive testing, but could instead rely on passive surveillance through the slaughterhouses.”

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.